Charles River Laboratories (CRL) Earnings Analysis
Charles River Laboratories (CRL) delivered mixed results in FY2026 on revenue of $21.1B versus the $21.3B estimate (+10.8% YoY) and EPS of $3.93. Below is the full Charles River Laboratories earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Charles River Laboratories (CRL) Earnings Analysis — key stats
Next earnings date
Feb 6, 2025
Latest reported quarter
FY2026
Earnings verdict
Mixed
Revenue
$21.1B (vs $21.3B est · -1.1% surprise · +10.8% YoY)
EPS
$3.93 (vs $3.71 est · +5.9% surprise · +29.5% YoY)
Share price
$195.89 (-0.9%)
Market cap
$1.03T
What you'll find
Next Charles River Laboratories (CRL) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Charles River Laboratories reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Charles River Laboratories (CRL)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Charles River Laboratories's next earnings date?
Charles River Laboratories's (CRL) next scheduled earnings date is Feb 6, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Charles River Laboratories (CRL) beat or miss earnings?
In FY2026, Charles River Laboratories (CRL) posted mixed results — revenue of $21.1B versus the $21.3B estimate (-1.1% surprise) and EPS of $3.93 versus $3.71 expected (+5.9% surprise). Magnisto decodes every Charles River Laboratories (CRL) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Charles River Laboratories (CRL) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Charles River Laboratories (CRL), anchored to the current $195.89 share price, so you can weigh the bull, base and bear cases for Charles River Laboratories side by side.
Is Charles River Laboratories (CRL) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Charles River Laboratories fits your own thesis and risk profile. This is research, not investment advice.